Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Cree

BAC

Mares

Hartung

HP.

Current therapeutic landscape in multiple sclerosis: An evolving treatment paradigm. Curr Opin Neurol 2019; 32(3): 365–377.

Fambiatos

Jokubaitis

Horakova

, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler 2020; 26: 79–90.

Lorscheider

Buzzard

Jokubaitis

, et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139: 2395–2405.

Brown

JWL

Coles

Horakova

, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187.

Kalincik

Brown

JWL

Robertson

, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: A cohort study. Lancet Neurol 2017; 16(4): 271–281.

Big data in MS—What can we learn from large international observational studies such as MSBase?

Abstract

Get full access to this article

References